In contrast, CTNNB1-mutant tumours, characterised by an immune-excluded microenvironment and resistance to PD-1 blockade [41], may benefit from therapies targeting the Wnt/β-catenin pathway, such as the small-molecule inhibitor PRI-724, currently under investigation [42]. This evidence concerns the gene CTNNB1 and neoplasm.